In contrast, Zhang observed a PDGFRBC843G mutation in a Ph-like ALL patient, which conditioned resistance to ABL TKIs and sensitivity to the CHZ868 multitarget kinase inhibitor [87]. This evidence concerns the gene ABL1 and acute lymphoblastic leukemia.